Latest BioInvent News & Updates
See the latest news and media coverage for BioInvent. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biopharmaceutical company developing cancer immunotherapies
bioinvent.com- Headquarters
- Lund, Sweden
- Company type
- Public company
- Number of employees
- 125–200
Latest news about BioInvent
Company announcements
-
BioInvent’s AGM elects new board members and approves incentive program
The meeting approves financial statements, no dividend, board fees, remuneration guidelines, long-term stock options, and share issue authorizations.
-
BioInvent publishes Q1 2026 interim report
Net sales SEK 13.4m, loss SEK 119.2m. Promising BI-1808 Phase 2a data in ovarian cancer; new board members nominated.
-
BioInvent presents BI-1808 plus KEYTRUDA data at 2026 ASCO
Data from Phase 2a trial in recurrent ovarian cancer shows 24% overall response rate, tripling pembrolizumab alone. Presentation is May 30, 2026.
-
BioInvent publishes Annual Report 2025
The report highlights advancements in BI-1808 and BI-1206 clinical programs, key 2025 events, financial position into Q1 2027, and 2026 catalysts.
Media coverage
-
Resolutions at BioInvent's Annual General Meeting 2026
LUND, SE / ACCESS Newswire / April 29, 2026 / The Annual General Meeting (AGM) of BioInvent International AB (BioInvent) (Nasdaq Stockholm:BINV) resolved to elect...
-
BioInvent Posts Strong Interim Data for BI‑1808 and KEYTRUDA Combo in Recurrent Ovarian Cancer
BioInvent International AB ( (SE:BINV)) has issued an update. BioInvent International has reported encouraging interim Phase 2a data for its first‑in‑class anti‑TNFR2 antibody BI‑1808 in...
-
BioInvent Ramps Up Oncology Profile With Dual KOL Events Around ASCO and EHA
BioInvent International will host two Key Opinion Leader events to showcase scientific and clinical advances in its oncology portfolio, particularly the anti-TNFR2 antibody BI-1808 and...
-
BioInvent International AB: Interim Report January - March 2026
LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV)"During the first quarter of 2026, our strategy remained centered on efficient resource...
Track BioInvent and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
BioInvent competitors & trending companies
Browse news for competitors to BioInvent and other trending companies.
Alligator Bioscience
Oncopeptides
Aura Biosciences
Repertoire Immune Medicines
Immutep
Imugene
Candel Therapeutics
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic